

# **Elise Nelson, LVN, CCRC**

Reveal Research Institute

Director of Research

12850 Dallas Parkway #300 Frisco, TX 75033

enelson@revealinstitute.com

P: (469)225-9920 F: (469)225-9924

---

## **Clinical Trials**

2024 A Phase 3, Randomized, Study of Intralesional Cemiplimab Versus Primary Surgery in Participants with Early Stage Cutaneous Squamous Cell Carcinoma (CSCC). Sponsored by Regeneron.

2024 A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1). Sponsored by Alumis.

2024 CorEvitas Adolescent AD Registry.

2024 CorEvitas Generalized Pustular Psoriasis Registry

2024 A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants with Nonsegmental Vitiligo. Sponsored by Incyte

2024 A Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Apogee

2024 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 3-Arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amltelimab by Subcutaneous Injection to Participants Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis (AD) Who Are On Background Topical Corticosteroids and Have Had An Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment. Sponsored by Sanofi.

2024 A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.

2023 A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy,

Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis. Sponsored by Takeda.

2023 A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Non-Pustular Palmoplantar and Genital Psoriasis. Sponsored by Bristol Myers Squibb.

2023 A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged 12 to 18 years With Moderate-to-severe Atopic Dermatitis. Sponsored by Amgen.

2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area. Sponsored by Janssen.

2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Sponsored by Janssen.

2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment. Sponsored by Janssen.

2023 A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab. Sponsored by Jerry Bagel.

2023 A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis. Sponsored by Abbvie.

2023 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa. Sponsored by Incyte.

2023 An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab. Sponsored by Eli Lilly.

2023 A Phase 3B/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Moderate-to-Severe Psoriasis. Sponsored by Bristol-Myers Squibb.

2023 PSoSA (PSoriasis Special Areas) - a US-based, Single-Arm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab. Sponsored by Eli Lilly.

2023 A Single Center, Observational Study to Evaluate the Effectiveness and Safety of Cryotherapy in combination with 10% ALA gel Red light PDT in the treatment of Actinic Keratosis on the Full Face. Sponsored by Jerry Bagel.

2023 A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (deucravacitinib) in Combination with Enstilar for Moderate to Severe Plaque Psoriasis. Sponsored by Jerry Bagel.

2023 Tralokinumab Real world Clinical use: An observational cohort study of atopic dermatitis patients prescribed tralokinumab. Sponsored by Leo Pharma.

2022 A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.

2022 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis. Sponsored by Janssen.

2022 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.

2022 Hidradenitis Suppurativa: Lutikizumab (ABT-981) Versus Placebo for Adult Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.

2022 Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination with Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis. Sponsored by Jerry Bagel.

2022 Inflammatory Skin Disease Treatment Identification Study. Sponsored by Castle Biosciences, Inc.

2022 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.

2021 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.

2021 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis. Sponsored by Arcutis Biotherapeutics, Inc.

2021 A Multi-Center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-Mechanisms in Patients with Atopic Dermatitis. Sponsored by Sanofi-Aventis Recherche & Développement.

2021 Risankizumab in Moderate to Severe Plaque Psoriasis Patients with Palmoplantar Involvement. Sponsored by Abbvie.

2021 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants with Moderate To Severe Hidradenitis Suppurativa. Sponsored by UCB Biopharma.

2021 A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Sponsored by Janssen.

2021 Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness. Sponsored by CorEvitas.

2021 A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared with Continued Use of Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

2021 A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.

2021 A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.

2021 A Phase 2b, Multicenter, Randomized, Placebo-and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants with Moderate to Severe Atopic Dermatitis. Sponsored by Janssen.

2021 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

2021 A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo. Sponsored by Arcutis Biotherapeutics, Inc.

2021 A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the "Cardigan II Study"). Sponsored by Brickell Biotech, Inc.

2021 A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Eli Lilly.

2021 A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Eli Lilly.

2021 An Exploratory, Multicenter, Observational Study to Examine RNA Biomarkers of Psoriasis Subjects Through the Application of the Mindera Kit Part 2 (STAMP-2). Sponsored by Mindera Corporation.

2020 A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis. Sponsored by Joel M Gelfand MD MSCE.

2020 A Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Prurigo Nodularis Who are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies are Not Advisable. Sponsored by Sanofi US Service, Inc.

2020 A Study to Test Long-Term Treatment with Spesolimab in People with Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies with Spesolimab. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

2020 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis. Sponsored by Eli Lilly.

2020 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.

2020 A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis. Sponsored by Arcutis Biotherapeutics, Inc.

2020 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Eli Lilly.

2020 A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled with topical therapies. Sponsored by Novartis.

2020 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Dermira.

2020 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.

2020 A Phase 3B Randomized, Double-Blind, Double-Dummy, Active Controlled Multi-Center Study Assessing the Efficacy and Safety of Abrocitinib Compared with Dupilumab in Adult Participants on Background Topical Therapy with Moderate to Severe Atopic Dermatitis. Sponsored by Pfizer.

2020 Open Label Study, Evaluating Taltz in combination with Enstilar (calcipotriene and betamethasone dipropionate) Foam in Psoriasis Patients. Sponsored by Jerry Bagel.

2020 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa. Sponsored by UCB.

2020 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination with HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Sponsored by Jerry Bagel.

2020 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis. Sponsored by Arcutis, Inc.

2020 A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis. Sponsored by PCORI.

2019 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.

2019 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp. Sponsored by Sun Pharma.

2019 Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP). Sponsored by Boehringer Ingelheim.

2019 A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults. Sponsored by Dermavant Sciences.

2019 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Abbvie.

2019 A 16-week, Randomized, Open Label, Multicenter Study to Assess the Superiority of Secukinumab over Guselkumab in the Complete Treatment of Ustekinumab-Resistant Psoriatic Plaques- Arrow. Sponsored by Novartis.

2019 A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis. Sponsored by Pfizer.

2019 An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers. Sponsored by Jerry Bagel.

2019 A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions. Sponsored by Target Pharmsolutions.

2019 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie.

2018 Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Abbvie.

2018 A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UCB.

2018 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UCB.

2018 A Randomized, Double Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Prurigo Nodularis. Sponsored by Menlo Therapeutics.

2018 A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies. Sponsored by Icahn School of Medicine at Mount Sinai.

2018 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Plaque Psoriasis. Sponsored by Menlo Therapeutics.

2018 A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults with Moderate-to-Severe Atopic Dermatitis Who are Candidates for Systemic Therapy. Sponsored by Leo Pharma.

2018 A Multi-Center, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.

2018 An Open-Label, Observational Study Evaluating Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Etanercept or Adalimumab. Sponsored by Jerry Bagel.

2018 A Single Center Study to Evaluate the Effectiveness and Safety of add on Enstilar® in Patients Using Otezla for Moderate to Severe Plaque Psoriasis. Sponsored by Jerry Bagel.

2018 A 24-Week Multicenter, Randomized, Double-Blind Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Sponsored by Eli Lilly.

2018 A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie.

2018 A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis. Sponsored by Bristol-Myers Squibb.

2018 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Mild to Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.

2018 A Phase 3, Multicenter, Randomized, Placebo and Active Comparator Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ( $\geq 6$  To  $< 18$  Years of Age). Sponsored by Janssen.

2018 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.

2018 Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Boehringer Ingelheim.

2018 Dupixent Atopic Dermatitis Photography Project. Sponsored by Sanofi.

2018 Skin Biopsy Analysis for Inflammatory Skin Disorders. Sponsored by Jerry Bagel.

2018 A Randomized, Double-Blind, Multicenter Study Assessing Short (16 Weeks) and Long-Term Efficacy (Up to 1 Year), Safety, and Tolerability of Sub-Cutaneous Secukinumab in Subjects of Body



Weight 90kg or Higher with Moderate to Severe Chronic Plaque-Type Psoriasis. Sponsored by Novartis.

2018 A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Prurigo Nodularis. Sponsored by Menlo Therapeutics Inc.

2018 An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritis. Sponsored by Menlo Therapeutics Inc.

2018 A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis. Sponsored by Regeneron.

2018 A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy. Sponsored by Abbvie.

2018 A Phase 3, Multicenter, Randomized, Double Blind Placebo and Active Comparator Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by UCB Biopharma SPRL.

2018 A Phase 3, Multicenter, Randomized, Double Blind Study With an Active Controlled Initial Treatment Period Followed by a Dose Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by UCB Biopharma SPRL.

2018 A Randomized, Double Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Plaque Psoriasis. Sponsored by Menlo Therapeutics Inc.

2017 Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris. Sponsored by Sienna Biopharmaceuticals.

2017 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003). Sponsored by Athenex, Inc.

2017 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Sponsored by Cutanea Life Sciences, Inc.

2017 An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients. Sponsored by Jerry Bagel.

2017 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS). Sponsored by AbbVie.

2017 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Pfizer.

2017 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis. Sponsored by Leo Pharma A/S.

2017 A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis of the Scalp. Sponsored by Celgene Corporation.

2017 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen.

2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals.

2017 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Explore changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment with Secukinumab, Compared to Placebo, and Up to 52 Weeks of Treatment with Secukinumab in Adult Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.

2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron.

2017 An Open-Label, Observational Study Evaluating Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.

2017 A Phase 2A Randomized Double Blind Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Pfizer.

2017 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.

2017 A Phase 3 Trial Comparing the Efficacy and Safety of LEO 90100 Aerosol Foam with the Aerosol Foam Vehicle Used Twice Weekly as Long-Term Maintenance Therapy in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma A/S.

2016 A Randomized, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis. Sponsored by DS Biopharma.

2016 A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 in Adult Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie.

2016 A Randomized, Placebo Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects with Moderate Chronic Plaque Type Psoriasis. Sponsored by Lycera Corp.

2016 A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis Sponsored by Eli Lilly.

2016 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD). Sponsored by Glenmark Pharmaceuticals Ltd.

2016 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of KD-025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. Sponsored by Kadmon.

2016 A 52-Week, Multi-Center, Randomized, Double-Blind, Study of Secukinumab (300mg) to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index and Investigators Global Assessment After 12 Weeks of Treatment, Compared to Ustekinumab, and to Assess Long-Term Safety, Tolerability, and Efficacy in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.

2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) in Patients with Scalp Psoriasis. Sponsored by Jerry Bagel.

2016 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed Therapy with Apremilast. Sponsored by Amgen.

2016 A Phase IIB, Randomized, Double-Blind, Randomized, Placebo Controlled, Parallel, Multicenter, Dose Ranging, Study To Evaluate the Efficacy and Safety Profile of PF-04965842 in Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Pfizer.

2015 A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.

2015 A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.

2015 A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.

2015 An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

2015 A Prosepctive, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor. Sponsored by Actelion Pharmaceuticals US, Inc.

2015 A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.

2015 An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who Participated in Previous Dupilimab Clinical Trials. Sponsored by Regeneron Pharmaceuticals, Inc.

2015 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

2015 Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Jerry Bagel.

2015 Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis. Sponsored by Qurient.

2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UBC Biopharma, SPRL.

2014 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC.

2014 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis. Sponsored by Novartis Pharmaceuticals Corporation.

2014 Characterization of Chronic Inflammatory Skin Disease. Sponsored by TRBIO.

2014 A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic. Sponsored by HRA.

2014 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma.

2014 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.

2014 A Non-Interventional, Prospective, Longitudinal Study of Patients with Moderate to Severe Chronic Plaque Psoriasis Who Are About to Initiate Treatment With A New Biologic.

2014 A 48 Week Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-Ranging, Active-Comparator Controlled (Ustekinumab), Double-Blind within Dose Groups of BI 655066). Sponsored by Boehringer Ingelheim.

2013 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% Versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.

2013 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex® Topical Suspension and Effect on Quality of Life. Investigator Sponsored.

2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. Sponsored by Promius.

2013 A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of the Investigational Drug in Plaque Psoriasis Patients. Sponsored by Maruho.

2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel-Group Clinical Trial to Assess the Safety and efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects with Papulopustular Rosacea. Sponsored by Bayer.

2013 A 12 Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsored by Eli Lilly.

2013 Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Eli Lilly.

2013 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.

2013 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex Topical Suspension and Effect on Quality of Life. Sponsored by LEO Pharma.

2013 Evaluation of HylatopicPlus Foam, HylatopicPlus Cream, and Aquaphor in Mild to Moderate Atopic Dermatitis Subjects to Assess Subject Experience Product Characteristics. Sponsored by Onset Dermatologics.

2013 A Phase 3 Trial Comparing Once Daily Treatment with LEO 90100 Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) with Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma.

2013 Clinical Trial To Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults. Sponsored by Anterios.

2012 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

2012 A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach of Ustekinumab in Subjects with Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.

2012 Phase II Randomized Double Blinded Placebo Controlled, Multiple-Dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways As Well As on Biomarkers of 12 Months Secukinumab 300 mg SC Treated Patients With Chronic Plaque-Type Psoriasis. Sponsored by Novartis.

2012 A Phase 2 Study Comparing Treatment With LEO 90100 with Betamethasone Dipropionate in LEO 90100 Vehicle and Calcipotriol in LEO 90100 Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma.

2012 A Phase 2 Study Comparing Treatment with LEO 90100 with Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris. Sponsored by LEO Pharma.

2012 A Phase 3 Randomized, Double-Blind, 12-week Vehicle-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Followed by a 40-Week Investigator-Blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Sponsored by Galderma.

2011 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.

2011 A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Assess the Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea. Sponsored by Galderma.

2011 Clinical Trial to Evaluate Sweat Production in Subjects with Primary Axillary Hyperhidrosis in Adults. Sponsored by Anterios, Inc.

2011 A Multicenter, Observational, Non-interventional, Narrative Study to Evaluate Patient-Reported Experiences of Living with Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.

2011 Collection of Blood Samples for Developing Assays to Measure Drug Levels and Anti-Drug Antibody Levels in Subjects Treated With Humira® (adalimumab) or Cimzia® (certoluzimab pegol.) Sponsored by Prometheus.

2011 A Phase 3, multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis. Sponsored by Celgene.

2010 Calcipotriol Plus Betamethasone Dipropionate Topical Suspension Compared to Betamethasone Dipropionate in the Topical Suspension Vehicle, Calcipotriol in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Psoriasis Vulgaris. Sponsored by Leo.

2010 A Single Center, Single-Arm, Open Label, Pilot Trial to Evaluate the Safety, Effectiveness, and Impact on Quality of Life of Adalimumab (Humira®) Treatment in patients with Vitiligo. Sponsored by Jerry Bagel.

2009 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

2009 A Phase 2 Study, Evaluating the Safety and Efficacy of Calcipotriol 25 mcg/g + Hydrocortisone 10 mg/g Ointment Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on Intertriginous Areas. Sponsored by Leo Pharma.

2009 A Phase 3, Multi-Center, Open Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Study with ABT-874. Sponsored by Abbott.

2009 A Single Center, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of HUMIRA in Combination with Narrowband UVB (NB-UVB) Phototherapy for the Treatment of Psoriasis. Sponsored by Jerry Bagel.

2009 A 10-Year, Post-Marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis. Sponsored by Abbott.

2009 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

2009 A Phase 2, Randomized, Double-Blind, Multi-Center, Multi-Country Placebo Controlled Parallel Study to Evaluate Clinical Activity, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LY2525623 Compared to Placebo in Adult Patients with Plaque Psoriasis. Sponsored by Eli Lilly.

2008 Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events (Response) in patients with Chronic Moderate to Severe Plaque Psoriasis. Sponsored by Genentech, Inc.

2008 A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients with Moderate-to-Severe Localized Psoriasis Lesions. Sponsored by Neostata.

2008 Observational Post-Marketing Safety Surveillance Registry of Enbrel (etanercept) for the Treatment of Psoriasis. Sponsored by Amgen.

2008 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study comparing Nycomed US Inc.'s Tacrolimus Ointment 0.1% to Protopic (Tacrolimus) Ointment 0.1% and both active treatments to a vehicle control in the treatment of Atopic Dermatitis. Sponsored by Nycomed.

2008 A Randomized, Double-Blind, Placebo-Controlled study to evaluate the efficacy and safety of Humira compared with placebo in adult patients with chronic moderate to severe plaque psoriasis of the hands and feet. Sponsored by Abbott.

2008 A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Sponsored by Janssen.

## **Publications**

2023 Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. *J Drugs Dermatol.* 2023 Aug 1;22(8):766-772. doi: 10.36849/jdd.6830.

2022 Bagel J, Nelson E. Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab. *J Drugs Dermatol.* 2022 Mar 1;21(3):235-240. doi: 10.36849/JDD.6396.PMID: 35254755



- 2022 Bagel J, Novak K, Nelson E. Adjunctive Use of Halobetasol Propionate–Tazarotene in Biologic-Experienced Patients With Psoriasis. *Cutis*. 2022 February;109(2):103-109 | doi:10.12788/cutis.0451
- 2021 Bagel J, Nelson E. Apremilast. Springer Nature Switzerland AG 2021. *Advances in Psoriasis*. [https://doi.org/10.1007/978-3-030-54859-9\\_11](https://doi.org/10.1007/978-3-030-54859-9_11).
- 2021 Bagel J, Butler B, Nelson E, Hetzel A. A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis. *J Drugs Dermatol*. 2021 Apr 1;20(4):442-449. doi: 10.36849/JDD.2021.5823.PMID: 33852233
- 2021 Weingberg J, Lebwohl M. *Advances in Psoriasis A Multisystemic Guide- Apremilast*. Bagel J, Nelson E. Springer Nature Switzerland AG 2021 DOI <https://doi.org/10.1007/978-3-030-54859-9>.
- 2020 Bagel J, Nelson E, Riley C, Hetzel A. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis. *J Drugs Dermatol*. 2020 Dec 1;19(12):1149-1155. doi: 10.36849/JDD.2020.5435.
- 2020 Bagel J, Nelson E, Zapata J, Hetzel A. Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. *Dermatol Ther (Heidelb)*. 2020 Dec;10(6):1383-1396. doi: 10.1007/s13555-020-00454-z. Epub 2020 Oct 13.
- 2018 Bagel J, Zapata J, Nelson E. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy. *J Drugs Dermatol*. 2018 Aug 1;17(8):845-850.
- 2018 Bagel, J. M.D., M.S., Nelson, Elise, LPN, CCRC & Keegan, B. M.D. PhD. Open-Label, Observational Pilot Study Evaluating Desoximetasone Topical Spray 0.25% Twice Daily in Patients With Psoriasis Being Treated With Biologic Agents, *Journal of Psoriasis and Psoriatic Arthritis* 2018, Vol. 3. pp. 10-14.
- 2018 Bagel J, Nelson E. An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. *J Clin Aesthet Dermatol*. 2018 May;11(5):27-29. Epub 2018 May 1.
- 2017 Bagel J, Nelson E, Keegan BR. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis. *J Drugs Dermatol*. 2017 Oct 1;16(10):957-962.